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Abstract. 
 
The 
 
Saccharomyces cerevisiae
 
 mating phero-
 
mone 
 
a
 
-factor is a prenylated and carboxyl methylated 
extracellular peptide signaling molecule. Biogenesis of 
the 
 
a
 
-factor precursor proceeds via a distinctive multi-
step pathway that involves COOH-terminal modifica-
 
tion, NH
 
2
 
-terminal proteolysis, and a nonclassical ex-
port mechanism. In this study, we examine the 
formation and fate of 
 
a
 
-factor biosynthetic intermedi-
ates to more precisely define the events that occur dur-
ing 
 
a
 
-factor biogenesis. We have identified four distinct 
 
a
 
-factor biosynthetic intermediates (P0, P1, P2, and M) 
by metabolic labeling, immunoprecipitation, and SDS-
PAGE. We determined the biochemical composition of 
each by defining their NH
 
2
 
-terminal amino acid and 
COOH-terminal modification status. Unexpectedly, we 
discovered that not one, but two NH
 
2
 
-terminal cleavage 
steps occur during the biogenesis of 
 
a
 
-factor. In addi-
tion, we have shown that COOH-terminal prenylation 
is required for the NH
 
2
 
-terminal processing of 
 
a
 
-factor 
and that all the prenylated 
 
a
 
-factor intermediates (P1, 
P2, and M) are membrane bound, suggesting that many 
steps of 
 
a
 
-factor biogenesis occur in association with 
membranes. We also observed that although the bio-
genesis of 
 
a
 
-factor is a rapid process, it is inherently in-
efficient, perhaps reflecting the potential for regulation. 
Previous studies have identified gene products that par-
ticipate in the COOH-terminal modification (Ram1p, 
Ram2p, Ste14p), NH
 
2
 
-terminal processing (Ste24p, 
Axl1p), and export (Ste6p) of 
 
a
 
-factor. The intermedi-
ates defined in the present study are discussed in the 
context of these biogenesis components to formulate an 
overall model for the pathway of 
 
a
 
-factor biogenesis.
 
I
 
n
 
 
 
Saccharomyces cerevisiae
 
, the peptide mating phero-
 
mones 
 
a
 
-factor and 
 
a
 
-factor function to promote con-
jugation between cells of the opposite mating type,
 
MAT
 
a
 
 and 
 
MAT
 
a
 
 (Marsh et al., 1991; Sprague and Thor-
ner, 1992). Like the peptide hormones secreted by higher
eukaryotes, the yeast mating pheromones are initially syn-
thesized as larger precursors that undergo posttransla-
tional modification and proteolytic processing before their
export from the cell. Despite their functional equivalence
as signaling molecules, the 
 
a
 
-factor and 
 
a
 
-factor phero-
mones are structurally quite dissimilar and exemplify dis-
tinct paradigms for biogenesis. The maturation of 
 
a
 
-factor
is well characterized and involves the “classical” secretory
 
pathway (ER
 
®
 
Golgi
 
®
 
secretory vesicles; Julius et al., 1984).
Subsequent to its translocation across the ER membrane,
the 
 
a
 
-factor precursor undergoes signal sequence cleav-
age, glycosylation, a series of proteolytic processing steps
in the lumenal compartments of the secretory pathway,
and then exits the cell via exocytosis (Fuller et al., 1986;
Sprague and Thorner, 1992). In contrast to our extensive
understanding of 
 
a
 
-factor maturation, our view of the
events involved in 
 
a
 
-factor biogenesis is still incomplete.
An important difference between the two pheromones is
that secretion of 
 
a
 
-factor is mediated by a “nonclassical”
export mechanism (Kuchler et al., 1989; McGrath and
Varshavsky, 1989; Michaelis, 1993). The purpose of the
present study is to delineate the steps of 
 
a
 
-factor biogene-
sis that occur before its export, by the identification and
characterization of 
 
a
 
-factor biosynthetic intermediates.
Mature bioactive 
 
a
 
-factor is a prenylated and methy-
lated dodecapeptide, derived by the posttranslational mat-
uration of a precursor encoded by the similar and func-
tionally redundant genes 
 
MFA1
 
 and 
 
MFA2
 
 (Brake et al.,
1985; Michaelis and Herskowitz, 1988). The structures of
the precursor and mature forms of 
 
a
 
-factor derived from
 
MFA1
 
 are shown in Fig. 1. The 
 
a
 
-factor precursor can be
subdivided into three functional segments: (
 
a
 
) the mature
portion (shaded in Fig. 1), which is ultimately secreted; (
 
b
 
)
the NH
 
2
 
-terminal extension; and (
 
c
 
) the COOH-terminal
CAAX motif (C is cysteine, A is aliphatic, and X is one of
many residues). As shown here, and also suggested by our
previous studies, the biogenesis of 
 
a
 
-factor occurs by an
ordered series of events involving first COOH-terminal
CAAX modification, then NH
 
2
 
-terminal processing, and
finally export from the cell (He et al., 1991; Michaelis,
1993; Sapperstein et al., 1994).
The COOH-terminal maturation of the 
 
a
 
-factor precur-
sor is directed by its CAAX sequence. The CAAX motif is
present at the COOH terminus of numerous eukaryotic
proteins, most notably the Ras proteins, and is known to
signal a triplet of posttranslational modifications. These
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include prenylation of the cysteine residue, proteolysis of
the COOH terminal AAX residues (VIA for 
 
a
 
-factor),
and methylation of the newly exposed cysteine carboxyl
group (Clarke, 1992; Zhang and Casey, 1996). The yeast
enzymes that mediate the modification of CAAX-termi-
nating proteins are known from genetic and biochemical
studies. 
 
RAM1
 
 and 
 
RAM2
 
 encode the subunits of the cy-
tosolic farnesyltransferase enzyme (Fujiyama et al., 1987;
He et al., 1991; Powers et al., 1986; Schafer et al., 1990).
An “AAX” endoprotease has been detected as a mem-
brane-associated activity in yeast extracts, although the
corresponding gene(s) remains elusive (Ashby et al., 1992;
Hrycyna and Clarke, 1992). 
 
STE14
 
 encodes the prenylcys-
teine-dependent carboxyl methyltransferase that mediates
methylation, the final step in modification of CAAX pro-
teins; Ste14p is also membrane associated (Hrycyna and
Clarke, 1990; Hrycyna et al., 1991; Marr et al., 1990; Sap-
perstein et al., 1994). In mutants (
 
ram1
 
, 
 
ram2
 
, and 
 
ste14
 
)
defective in CAAX modification, biologically active 
 
a
 
-fac-
tor is not produced.
The events involved in the NH
 
2
 
-terminal proteolytic pro-
cessing of the 
 
a
 
-factor precursor are less well-defined than
those of COOH-terminal maturation. It was recently shown
that a protease encoded by the 
 
AXL1
 
 gene is required for
one step of the NH
 
2
 
-terminal processing of 
 
a
 
-factor (Adames
et al., 1995). Axl1p belongs to the insulin-degrading enzyme
(IDE)
 
1
 
 subfamily of proteases; an 
 
AXL1
 
 homologue, Ste23p,
was also found to perform a role at least partially redun-
dant to that of Axl1p in 
 
a
 
-factor processing (Adames et al.,
1995). Recently, we have identified another gene, 
 
STE24
 
,
whose product participates in the NH
 
2
 
-terminal processing
of the 
 
a
 
-factor precursor in a manner distinct from Axl1p
and Ste23p (Fujimura-Kamada and Michaelis, 1997).
Based on a priori inspection of the precursor and mature
forms of 
 
a
 
-factor (Fig. 1), a single NH
 
2
 
-terminal proteolytic
cleavage event (between residues N21 and Y22) might
have been predicted; however, we provide evidence in the
present study that the proteolytic processing of the NH
 
2
 
-
terminal extension of the 
 
a
 
-factor precursor occurs in two
distinct steps.
The final event in 
 
a
 
-factor biogenesis is the export of the
fully matured pheromone from the cell. The absence of a
canonical NH
 
2
 
-terminal signal sequence in the 
 
MFA1
 
 and
 
MFA2
 
 sequences, as well as the lack of effect upon 
 
a
 
-fac-
tor secretion of 
 
sec
 
 mutants blocked at various steps in the
classical secretory pathway, led to the suggestion of a non-
classical export mechanism for 
 
a
 
-factor export (McGrath
and Varshavsky, 1989; Sterne, 1989). Indeed, 
 
a
 
-factor ex-
port is now known to be mediated by Ste6p, a member of
the ATP-binding cassette (ABC) superfamily of proteins
(Kuchler et al., 1989; McGrath and Varshavsky, 1989). ABC
proteins carry out the ATP-dependent membrane translo-
cation of a variety of compounds, including small peptides,
hydrophobic drugs, and even prenylcysteine derivatives,
 
by an uncharacterized mechanism (Gottesman and Pastan,
1993; Zhang et al., 1994). It is notable that 
 
a
 
-factor under-
goes COOH-terminal modification and NH
 
2
 
-terminal pro-
teolytic maturation before Ste6p-mediated membrane trans-
location. This order of events contrasts with those of the
biogenesis of the 
 
a
 
-factor precursor and other classical
secretory substrates, which undergo ER membrane trans-
location first and are matured only subsequently.
In the present study, we aimed to elucidate the events
that occur during 
 
a
 
-factor biogenesis, before its export
from the cell. Our approach was to identify 
 
a
 
-factor bio-
synthetic intermediates, determine their chemical compo-
sition and localization properties, and examine the effi-
ciency of their formation and the effects of an 
 
a
 
-factor
CAAX mutation on their formation. In addition to identi-
fying the biosynthetic intermediates we expected, which
include the unmodified 
 
a
 
-factor precursor (P0), the COOH-
terminally modified 
 
a
 
-factor precursor (P1), and mature
 
a
 
-factor (M), we unexpectedly uncovered a novel and un-
anticipated intermediate. This species, designated P2, is
fully COOH-terminally modified and has had only a seg-
ment of its NH
 
2
 
-terminal extension proteolytically re-
moved. The existence of the P2 intermediate provides evi-
dence that an additional unpredicted step occurs during
the NH
 
2
 
-terminal processing of the 
 
a
 
-factor precursor. The
biosynthetic intermediates we identify here, considered to-
gether with known 
 
a
 
-factor biogenesis components, are pre-
sented in terms of a comprehensive model for the 
 
a
 
-factor
biogenesis pathway.
 
Materials and Methods
 
Yeast Strains and Media
 
The yeast strains used in this study are listed in Table I. The 
 
MAT
 
a
 
 
 
a
 
-fac-
tor null strains SM1229 (
 
mfa1-
 
D
 
1::LEU2 mfa2-
 
D
 
1::URA3
 
; Michaelis and
Herskowitz, 1988), SM1458 (
 
mfa1-
 
D
 
1::LEU2 mfa2-
 
D
 
2::lacZ
 
), and SM2331
(
 
mfa1-
 
D
 
1 mfa2-
 
D
 
1
 
) were used to harbor plasmids carrying either wild-
type or mutant 
 
MFA1.
 
The 
 
a
 
-factor null strain SM1458 was produced in several steps: (
 
a
 
) To
generate a disruption allele of 
 
MFA2
 
 that is marked by the 
 
Escherichia
coli lacZ
 
 gene, a 3.3-kb BamHI fragment from pMC1871 (Casadaban et al.,
1983) was ligated into pSM29 (Michaelis and Herskowitz, 1988) that had
been digested with BamHI to drop out a 0.5-kb BamHI fragment contain-
ing the COOH-terminal 
 
MFA2
 
 coding region and its downstream se-
quences. The resulting plasmid, pSM38, contains an mfa2 null allele
(mfa2-D2::lacZ) in which the COOH-terminal seven codons (32–38) of
MFA2 are deleted, and the MFA2 amino terminal region is fused in frame
to lacZ; for simplicity, this allele is designated mfa2::lacZ. (b) To integrate
the mfa2 null mutation by one-step gene replacement, a HindIII restric-
tion digestion of pSM38 was cotransformed, together with 5 mg of the 2m
LEU2 plasmid YEp13, into SM1058. Leu1 colonies were tested for blue
color on an X-Gal filter to determine which cotransformants also con-
tained the mfa2::lacZ gene replacement; blue colonies represented 2% of
the total transformants. (c) One blue cotransformant that had been al-
lowed to lose YEp13 was designated SM1179; the presence of the ex-
pected chromosomal mfa2::lacZ mutation in this strain was confirmed by
Southern analysis. (d) Finally, two sequential crosses were carried out to
produce the a-factor null mutant SM1458. SM1179 (MATa mfa2::lacZ)
was crossed to the otherwise isogenic strain SM1059 (MATa MFA2), and
a MATa segregant, SM1196, was obtained. Next, SM1196 (MATa MFA1
mfa2::lacZ) was crossed to SM1225 (MATa mfa1::LEU2) and an a-factor-
less MATa segregant, designated SM1458 (MATa mfa1::LEU2 mfa2::lacZ),
was chosen. SM1458 is a convenient recipient for the MFA1-containing
TRP1 and URA3 plasmids used in this study.
The a-factorless strain SM2331 (mfa1-D1 mfa2-D1) contains the same
deletions as those present in SM1229 (mfa1-D1::LEU2 mfa2-D1::URA3),
except that in SM2331, these deletions are unmarked. SM2331 was con-
1. Abbreviations used in this paper: ABC, ATP-binding cassette; E, extra-
cellular; I, intracellular; M, mature species of a-factor; M(E), extracellular
mature a-factor; M(I), intracellular mature a-factor; P0, unmodified a-fac-
tor precursor; P1, fully COOH-terminally modified precursor species of a
factor; P2, fully COOH-terminally modified, partially NH2-terminally
cleaved precursor species of a-factor; PTH, phenylthiohydrantoin; SAM,
S-adenosyl-l-methionine; 5-FOA, 5-fluoroorotic acid.Chen et al. Biogenesis of Yeast a-Factor 253
structed using URA3 integrating plasmids pDH6 (mfa1-D1) and pDH9
(mfa2-D1), kindly provided by D. Hagen and G. Sprague (University of
Oregon, Eugene, OR). pDH6 contains the 1.5-kb EcoR1-XbaI fragment
from pSM82 (Michaelis and Herskowitz, 1988), in which codons 2–36 of
MFA1 are deleted and marked by a BamH1 recognition site. pDH9 con-
tains a genomic DNA fragment that was originally 3.5 kb, from which the
0.8-kb BamH1-SphI fragment including and flanking MFA2 was deleted.
To construct the strain SM2331, two sequential two-step gene disruptions
were carried out: First, pDH9 (URA3 mfa2-D1) was linearized with Hind-
III and transformed into SM1058. From one Ura1 transformant, Ura2 de-
rivatives were selected on 5-FOA and examined by Southern analysis,
yielding strain SM2165, which contains the mfa2-D1 mutation. Second,
pDH6 (URA3 mfa1-D1) linearized with SphI was transformed into
SM2165, a Ura1 transformant was obtained, and Ura2 derivatives were
selected on 5-FOA. Mating of the Ura2 derivatives was tested, and one
mating-defective strain, SM2331, was shown by Southern analysis to con-
tain both the mfa1-D1 and mfa2-D1 deletions.
Complete media (YEPD), synthetic dropout media (SC-URA and
SC-TRP), and SD minimal media were prepared as described previously
(Michaelis and Herskowitz, 1988), except that the drop-out media lack
l-methionine and l-cysteine. Where necessary, SD media was supple-
mented with l-histidine (20 mg/ml), l-tryptophan (20 mg/ml) or l-leucine
(30 mg/ml), and uracil (20 mg/ml). Strains were grown at 308C, unless oth-
erwise specified.
Plasmids and DNA Manipulation
The plasmids used in this study are listed in Table II. Plasmid pSM118,
used for in vitro transcription and translation of a-factor, was constructed
by cloning a 0.45-kb Sau3A MFA1-containing fragment from pSM39
(Michaelis and Herskowitz, 1988) into the BamHI site of pGEM1 (Promega,
Madison, WI). In pSM118, a-factor expression is driven by the SP6 pro-
moter, which lies 85 bases upstream of the MFA1 ATG. Plasmid pSM217,
a 2m URA3 vector, was constructed by digesting pRS306 (Sikorski and
Hieter, 1989) with AatII, made blunt-ended by Klenow polymerase, and
ligating to it a 1.9-kb filled-in HindIII-PstI fragment from YEp24, which
Table I. S. cerevisiae Strains Used in This Study
Strains Relevant Genotype Source
S288C MATa gal2 Mortimer and Johnston, 1986
S1278B MATa Brandriss and Magasanik, 1979
SK-1 MATa ho::LYS2 lys2 ura3 Alani et al., 1987
SM1058* MATa MFA1 MFA2 trp1 leu2 ura3 his4 can1 Michaelis and Herskowitz, 1988
SM1059‡ MATa MFA1 MFA2 trp1 leu2 ura3 his4 can1 Michaelis and Herskowitz, 1988
SM1179‡ MATa MFA1 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 This study
SM1196‡ MATa MFA1 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 This study
SM1225‡ MATa mfa1-D1::LEU2 MFA2 trp1 leu2 ura3 his4 can1 Michaelis and Herskowitz, 1988
SM1227‡ MATa MFA1 mfa2-D1::URA3 trp1 leu2 ura3 his4 can1 Michaelis and Herskowitz, 1988
SM1229‡ MATa mfa1-D1::LEU2 mfa2-D1::URA3 trp1 leu2 ura3 his4 can1 Michaelis and Herskowitz, 1988
SM1458‡ MATa mfa1-D1::LEU2 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 This study
SM1585‡ MATa mfa1-D1::LEU2 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 p[2m MFA1 URA3] Transformant of SM1458 with pSM219
SM1680‡ MATa mfa1-D1::LEU2 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 p[2m mfa1-DVIA URA3] Transformant of SM1458 with pSM258
SM1682‡ MATa mfa1-D1::LEU2 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 p[2m mfa1-C33S URA3] Transformant of SM1458 with pSM257
SM1710‡ MATa mfa1-D1::LEU2 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 p[CEN MFA1 URA3] Transformant of SM1458 with pSM233
SM1762‡ MATa mfa1-D1::LEU2 mfa2-D2::URA3 trp1 leu2 ura3 his4 can1 p[2m MFA1 TRP1] Transformant of SM1229 with pSM463
SM1829‡ MATa mfa1-D1::LEU2 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 p[CEN MFA1 TRP1] Transformant of SM1229 with pSM464
SM1865‡ MATa ram1::URA3 trp1 leu2 ura3 his4 can1  He et al., 1991
SM1932‡ MATa mfa1-D1::LEU2 mfa2-D2::lacZ trp1 leu2 ura3 his4 can1 p[2m mfa1-I23M URA3] Transformant of SM1458 with pSM490
SM2165‡ MATa MFA1 mfa2-D2-D1 trp1 leu2 ura3 his4 can1 This study
SM2331‡ MATa mfa1-D1 mfa2-D1 trp1 leu2 ura3 his4 can1 This study
SM2891‡ MATa mfa1-D1 mfa2-D1 trp1 leu2 ura3 his4 can1 p[CEN MFA1 URA1] Transformant of SM2331 with pSM233
SM2892‡ MATa MFA1 mfa2:-D2:lacZ trp1 leu2 ura3 his4 can1 p[CEN URA3] Transformant of SM1179 with pSM316
SM2893‡ MATa mfa1-D1 mfa2-D1 trp1 leu2 ura3 his4 can1 p[2m MFA1 URA3] Transformant of SM2331 with pSM219
SM3019‡ MATa mfa1-D1::LEU2 MFA2 trp1 leu2 ura3 his4 can1 p[CEN URA3] Transformant of SM1225 with pSM316
SM3020‡ MATa mfa1-D1 mfa2-D1 trp1 leu2 ura3 his4 can1 p[CEN URA3]  Transformant of SM2331 with pSM630
SM3021‡ MATa mfa1-D1 mfa2-D1 trp1 leu2 ura3 his4 can1 p[2m MFA2 URA3] Transformant of SM2331 with pSM628
*SM1058 was formerly designated EG123 (Siliciano and Tatchell, 1984). SM1059 was formerly designated 246.1.1 (Siliciano and Tatchell, 1984).
‡These strains are isogenic with SM1058.
Figure 1. Structure of pre-
cursor and mature forms of
a-factor encoded by MFA1.
The a-factor precursor en-
coded by MFA1 is shown
with the NH2-terminal exten-
sion, COOH-terminal CAAX
motif, and mature portion
(shaded gray) indicated. Ev-
ery fifth residue is numbered.
Mature a-factor derived from
this precursor is modified on
its COOH-terminal cysteine
residue by a farnesyl moiety
and a carboxyl methyl group,
as indicated.The Journal of Cell Biology, Volume 136, 1997 254
contains  2m DNA. To construct various a-factor plasmids, the 1.6-kb
EcoRI-XbaI fragment bearing MFA1 was subcloned from pSM18 (Michaelis
and Herskowitz, 1988) into the EcoR1 and XbaI sites in the polylinker of
pRS316 (Sikorski and Hieter, 1989), pSM217, pRS314 (Sikorski and
Hieter, 1989), and pSM363, yielding the MFA1 plasmids pSM233, pSM219,
pSM464, and pSM463, respectively.
E. coli and yeast transformations were performed essentially as de-
scribed previously (Elble, 1992; Rose et al., 1990). All cloning was carried
out directly in low melting temperature agarose, as described (Sambrook
et al., 1989). The E. coli strains MH1 (Hall et al., 1984) and DH5a (Hana-
han, 1983) were used to propagate plasmids.
Site-directed Mutagenesis
MFA1 mutations were generated by site-directed oligonucleotide mu-
tagenesis (Kunkel et al., 1987). The oligonucleotide sequences used to
generate a-factor mutants are shown here with the mutagenic residues un-
derlined. C33S: 59-AAGCAATAACACTTGCTGGGTCCC-39 (oSM24);
I23M: 59-GACACCTTTGATCATATAGTTGTCC-39 (oSM70); DVIA
(36-38): 59-ACGCAGAAACTA/ACATGCTGGGTC-39 (oSM25). The
plasmid pSM233 (CEN MFA1 URA3) was the template for generating
mutants. Preparation of single-stranded phage, extraction of DNA, and
the in vitro elongation reaction were carried out using the Muta-gene
Phagemid in vitro mutagenesis kit from Bio Rad Laboratories (Hercules,
CA). DNA sequencing was carried out on double-stranded plasmid, prop-
agated in DH5a, and prepared by the boiling mini prep procedure (Sam-
brook et al., 1989) using the Sequenase kit from Amersham (Arlington
Heights, IL). The primer used to sequence a-factor mutations was oSM17:
59-CTGTAACTGTTTCTCGG-39, which anneals to the 59 upstream re-
gion of MFA1. Desired mutations were obtained at a frequency between
10 and 50%. Mutants were subcloned from the pSM233 parental plasmid
into pSM217 to produce 2m plasmid versions, which were designated
pSM257 (mfa1-C33S), pSM490 (mfa1-I25M), and pSM258 (mfa1-DVIA).
The sequence of all MFA1 mutant plasmids was reverified after reisola-
tion from yeast strains.
Generation of Rabbit Polyclonal a-Factor Antiserum
The dodecapeptide corresponding to the unmodified mature a-factor se-
quence encoded by MFA1, YIIKGVFWDPAC, was chemically synthe-
sized by Dr. P. Shenbagamurthi at The Johns Hopkins School of Medicine
Protein-Peptide-DNA Facility (Baltimore, MD). To generate a-factor an-
tiserum, the unconjugated dodecapeptide was resuspended in Freund’s
complete adjuvant and directly injected into rabbits by Hazelton Research
Products, Inc. (Denver, PA). Subsequent boosts were carried out in Freund’s
incomplete adjuvant. The immune serum was initially screened by ELISA
tests versus the a-factor dodecapeptide and was further analyzed by im-
munoprecipitation. Antiserum from rabbit antisera designated Ab-9-137
and Ab-499 were shown to immunoprecipitate all a-factor species with
equivalent efficiency (Chen, 1993).
Metabolic Labeling and Preparation of Intracellular 
and Extracellular a-Factor
Yeast cells were grown to log phase in synthetic media to OD600 0.5–1.0. 5
OD600 U of cells were used for each sample to be analyzed, unless other-
wise indicated. Before labeling, cells were harvested by centrifugation at
5,000 g for 5 min, washed once with SD media, and resuspended in 0.5 ml
fresh media in a polypropylene tube at room temperature. All labelings
were performed at 308C, unless otherwise specified.
Steady-state labeling was carried out in SC dropout media for 30 min
with 150 mCi [35S]cysteine (1,160 Ci/mmol, 11 mCi/ml; ICN Biomedicals,
Inc., Irvine, CA) per sample (5 OD600 U of cells). Approximately 25% of
the added radioactivity is incorporated into cells during this period;
[35S]cysteine uptake remains linear for up to z90 min. Pulse labeling was
carried out in SD media plus necessary supplements for a short time (1–5
min) with 150 mCi [35S]cysteine added for each time point to be analyzed.
In SD media, the half-time of [35S]cysteine incorporation is z7 min. The
chase was initiated by addition of 10 ml of 503 chase mix (1 M cysteine,
1 M methionine) per each time point. Immediately after labeling, cells
were split into separate tubes representing each time point of the chase. It
was necessary to treat each sample separately because a-factor sticks to
the walls of the polypropylene tubes and total extracellular a-factor must
be recovered by combining the culture fluid and tube wash for each time
point of the chase (see below). The chase was terminated by addition of
0.5 ml ice-cold azide stop mix (40 mM cysteine, 40 mM methionine, 20 mM
NaN3, 500 mg/ml BSA [Miles Laboratories, Elkhart, IN]). Samples were
kept at 48C after termination of the chase. Labeled cells and culture fluid
were moved from the “chase tube” to a new tube and separated by centrif-
ugation in a microfuge at top speed (13,600 g) for 1 min; the chase tube
was retained for the tube wash (see below). The pellet was designated the
intracellular (I) fraction, and the culture supernatant together with the
material obtained from the tube wash (below) is designated the extracel-
lular (E) fraction.
Proteins from the I and E fractions were concentrated and denatured
before immunoprecipitation by the following procedures. The pellet (I frac-
tion) was washed once with 1 ml cold distilled H2O and resuspended in 1 ml
cold distilled H2O. Cells were lysed by the addition of 150 ml cold NaOH–
b-mercaptoethanol (1.0 ml 2 M NaOH; 80 ml b-mercaptoethanol), fol-
lowed by incubation on ice for 15 min. Proteins in the I fraction were pre-
cipitated by adding 150 ml cold 50% TCA and incubating on ice for 15
min. After centrifugation at 13,600 g for 15 min at 48C, the supernatant
Table II. Plasmids Used in This Study
Plasmid Vector MFA1 genotype Yeast marker Source
pDH6 pRS306 mfa1-D1 URA3 D. Hagen and G. Sprague
pDH9 pRS306 mfa2-D1 URA3 D. Hagen and G. Sprague
pMC1871 pBR322-LacZ 22 Casadaban et al. 1983
pRS316 CEN 2 URA3 Sikorski and Hieter, 1989
pRS314 CEN 2 TRP1 Sikorski and Hieter, 1989
pRS424 2m2 TRP1 Christianson et al., 1992
pSM18 pUC18 MFA1 2 Michaelis and Herskowitz, 1988
pSM29 pUC18 MFA2 2 Michaelis and Herskowitz, 1988
pSM38 pUC18 mfa2-D2::lacZ 2 This study
pSM32 pUC18 mfa1-D1 2 Michaelis and Herskowitz, 1988
pSM118 pGEM1 SP6-MFA1 2 This study
pSM217 2m2 URA3 This study
pSM219 2m MFA1 URA3 This study
pSM233 CEN MFA1 URA3 This study
pSM257 2m mfa1-C33S URA3 This study
pSM258 2m mfa1-DVIA URA3 This study
pSM463 2m MFA1 TRP1 This study
pSM464 CEN MFA1 TRP1 This study
pSM490 2m mfa1-I23M URA3 This study
pSM628 2m MFA2 URA3 This study
pSM630 CEN MFA2 URA3 This studyChen et al. Biogenesis of Yeast a-Factor 255
was removed, the precipitated proteins were resuspended in 30 ml 23
Laemmli sample buffer (20% glycerol, 10% b-mercaptoethanol, 4.3%
SDS, 0.125 M Tris-HCl, pH 6.8, and 0.2% bromophenol blue), and the
sample was neutralized by the addition of 2 M Tris base when necessary,
followed by heating at 1008C for 3 min. Proteins from the culture fluid
portion of the E fraction (above) were precipitated by addition of an
equal volume of 20% cold TCA, incubation at 48C for 15 min, and centrif-
ugation at 13,600 g for 15 min at 48C. The pellet was resuspended in 20 ml
23 Laemmli sample buffer and neutralized with 2 M Tris base. Since a sig-
nificant portion of extracellular a-factor remains bound to the polypropy-
lene chase tube retained above, this tube was rinsed four times with dis-
tilled H2O, and bound proteins were eluted from its sides with 0.5 ml
n-propanol (Sterne, 1989). The n-propanol eluate was dried in a speed
vacuum concentrator with heat. This tube wash sample was resuspended in 10
ml 13 Laemmli sample buffer and combined with 20 ml of the E fraction
already in sample buffer (above) and heated at 1008C for 3 min. By com-
bining the a-factor from culture fluid and a-factor eluted from the chase
tube, quantitative recovery of extracellular a-factor is achieved.
Immunoprecipitation of a-Factor
For immunoprecipitation, I and E samples were diluted with 1.3 ml immu-
noprecipitation buffer (50 mM Tris-HCl, pH 7.5, 1.0% Triton X-100, 150 mM
NaCl, 1 mM PMSF, 0.5% Trasylol) and cleared of insoluble material by
centrifuging for 1 min at 13,500 g. Samples were transferred into new
tubes, avoiding the insoluble pellet, a-factor rabbit antiserum (10 ml) of
Ab-9-137 or Ab-499 (see Figs. 8 and 9) was added, and antigen–antibody
complex formation was allowed to proceed overnight at 48C. This amount
of antiserum was shown to represent an excess of antibody in these immu-
noprecipitation reactions (Chen, 1993). It should be noted that a-factor
does not bind to polypropylene in the presence of 1% Triton X-100. To
collect immunoprecipitates, a 45-ml aliquot of protein A–Sepharose CL-4B
beads (Pharmacia Fine Chemicals, Piscataway, NJ) suspended in immuno-
precipitation buffer (1:3 beads/total volume ratio) was added and the
tubes were gently agitated at 48C for 60 min. The beads were collected by
a 15-s spin at 13,600 g, washed four times with immunoprecipitation wash
buffer A (0.1% Triton X-100, 0.02% SDS, 150 mM NaCl, 50 mM Tris-
HCl, pH 7.5, 5 mM EDTA, 1 mM PMSF, 0.5% Trasylol), and once with
immunoprecipitation wash buffer B (150 mM NaCl, 50 mM Tris-HCl, pH
7.5, 5 mM EDTA, 1 mM PMSF, 0.5% Trasylol). After the final wash,
bound immune complexes were released from the beads by the addition
of 30 ml 23 Laemmli sample buffer. Samples were heated at 1008C for 3
min before SDS-PAGE.
SDS-PAGE Analysis of a-Factor
It was necessary to modify the classical SDS-PAGE method (Laemmli,
1970) to resolve the I species of a-factor, which range in molecular mass
from z1.6 to 4.5 kD. In addition to the small size of a-factor, the lipid
modification and extreme hydrophobicity of a-factor contribute to its un-
usual migration properties. Four aspects of the SDS-PAGE system were
optimized. First, different acrylamide percentages (12–20%) were tested,
keeping the acrylamide/Bis ratio constant at 30:08. Separation of the P1,
P2, and M species of a-factor was found to be optimal at 15–16% acryl-
amide, which represented a compromise between separation of precursor
(P1, P2) from mature (M) a-factor versus compression of P1 and P2 pre-
cursor bands. The second critical parameter is the pH of the 43 Laemmli
lower stock buffer used in the separation gel. Whereas resolution of the
P1 and P2 species of a-factor is optimal at pH 8.8, these species cannot be
resolved at pH 9.0. A third important factor is that a-factor gels must be
run at a relatively high current (constant current 5 50–65 mA) to achieve
optimal separation. Electrophoresis at a lower current results in “fuzzy”
a-factor bands. Finally, the separation of a-factor intermediates is very
sensitive to sample overloading. In general, immunoprecipitates derived
from ,1 OD600 U of cells were loaded in each gel lane. The addition of
significantly more protein resulted in broad fuzzy bands. Electrophoresis
of a-factor was carried out according to the modifications of the standard
Laemmli procedure described above, using prestained low range molecu-
lar weight markers (Gibco BRL, Gaithersburg, MD) to standardize gel runs.
After electrophoresis, gels were fixed in 10% acetic acid for 15 min,
rinsed in distilled H2O for 5 min, and soaked in 0.7 M Na salicylate, pH
7.0, for 15 min. Gels were dried under a vacuum at 808C and subjected to
autoradiography at 2808C. Alternatively, the salicylate step was omitted
and dried gels were subjected to Phosphorimager analysis (Molecular Dy-
namics, Inc., Sunnyvale, CA).
In Vitro Transcription and Translation
To generate the unmodified a-factor precursor, an SP6-MFA1 construct
was transcribed and translated in vitro. Briefly, 10 mg of pSM118 (SP6-
MFA1) was linearized by EcoRI-HindIII digestion, extracted twice with
phenol, once with phenol/CHCl3 (1:1), precipitated with ethanol, and re-
suspended in TE, pH 8.0. The SP6-MFA1 DNA was transcribed (Ribo-
probe System Kit; Promega) with 1 ml SP6 RNA polymerase (20 U/ml) at
378C for 60 min. After transcription, the RNA was extracted twice with
phenol, once with phenol/CHCl3 (1:1), precipitated with ethanol, and re-
suspended in DEPC-treated H2O. Before translation, the RNA template
was heated at 658C for 10 min and then translated using 25 ml wheat germ
extract (Wheat Germ Extract System; Promega) in the presence of 100 mM
potassium acetate, 0.1 mM cold amino acid–cysteine mix, and 25 mCi
[35S]cysteine (1,160 Ci/mmol, 11 mCi/ml; ICN Biomedicals). After incuba-
tion at 258C for 2 h, an equal volume of cold 50% TCA was added, precip-
itated proteins were pelleted, the pellet was resuspended in 30 ml 23
Laemmli sample buffer, and neutralized by the addition of 2 M Tris base,
if necessary. Precursor forms of a-factor were immunoprecipitated using
a-factor antiserum, as described above.
Vapor Phase Equilibrium Assay to Detect a-Factor 
Methyl Esters
To determine whether a particular species of a-factor contained a car-
boxyl methyl ester modification, [3H]S-adenosyl methionine (SAM) label-
ing and methylation assays were carried out, based on a previously de-
scribed procedure (Clarke et al., 1988; Hrycyna et al., 1991). 10 OD600 U
of yeast cells were double labeled with 300 mCi [35S]cysteine and 100 mCi
[3H]methyl AdoMet (84 Ci/mmol, 0.55 mCi/ml) from Dupont/NEN
(Boston, MA) for 5 min in SD media with appropriate supplements. For
the mfa1-C33S mutant (strain SM1682 that contains pSM257), 300 mCi
Trans-35S label from Amersham (Arlington Heights, IL) was substituted
for [35S]cysteine. After centrifugation at 13,600 g for 1 min, the cell pellet,
representing the I fraction, was washed with cold distilled H2O, resus-
pended in cell lysis buffer (50 mM potassium phosphate buffer, pH 7.4,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 1 mM b-mer-
captoethanol, 1 mM PMSF, 0.5% Trasylol), and lysed in the presence of
0.5 g baked zirconium beads (0.5 mm in diameter) obtained from Biospec
Products (Bartlesville, OK) by vortexing six times in 1-min bursts at 48C,
followed by chilling on ice. The cell lysate was removed from the beads.
The remaining lysate was obtained by washing twice with 0.5 ml cell lysis
buffer, and all three supernatant fractions were pooled. 10 ml of a-factor
antiserum was added to this lysate (1.4 ml total) directly. Immunoprecipi-
tation, SDS-PAGE, fixation, and autoradiography were carried out as de-
scribed above, except that the salicylate treatment step was omitted.
After visualization by autoradiography, intracellular a-factor interme-
diates in the dried gel were cut out as 0.4-cm slices, placed in a polypropy-
lene microcentrifuge tube, and mixed with 500 ml 1 M NaOH to hydrolyze
methyl esters to methanol. Immediately after the addition of NaOH, the
microfuge tube, with its cap open, was placed in a 20-ml scintillation vial
containing 5 ml of ASC2 scintillation fluid from Amersham, and the vial
was tightly capped. Care was taken not to allow the scintillation fluid to
directly contact the NaOH gel slices. After 24–36 h at 378C, the microcen-
trifuge tube was removed, and the radioactivity that had been partitioned
by diffusion of [3H]methanol into the scintillation fluid was assayed in a
liquid scintillation counter. Total [35S]cysteine incorporation was assayed
by adding 1 ml of Protosol tissue solubilizer from New England Biolabs
(Beverly, MA) to the gel slices after completion of the methylation assay
and allowing them to incubate for 6 h at 558C. The entire tube with its con-
tents was directly placed into 10 ml of OCS organic counting scintillation
fluid from Amersham, and was counted in a liquid scintillation counter.
Radiolabeled Peptide Sequence Analysis
10 OD600 U of yeast cells were labeled with 500 mCi l-[2,3,4,5-3H]proline
(91 Ci/mmol, 1 mCi/ml; Amersham), l-[4,5-3H]lysine (102 Ci/mmol, 5 mCi/
ml; Amersham), or Trans-35S label (1,144 Ci/mmol, 12 mCi/ml; ICN Phar-
maceuticals, Inc., Irvine, CA) for 5 min in SD media with appropriate sup-
plements. Labeled cells and culture fluid were collected, and I and E frac-
tions were prepared as described above for [35S]cysteine-labeled samples.
After electrophoresis, the gel was placed in transfer buffer (25 mM Tris-
HCl, pH 8.2, 192 mM glycine, 10% methanol [vol/vol]) to equilibrate for
15 min. Transfer of proteins from the gel to Immobilon polyvinyldifluo-
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70 V for 30 min. After removal of excess glycine by rinsing the blot in dis-
tilled H2O for 10 min, the membrane was air dried and subjected to auto-
radiography. 3H-labeled bands were visualized on film, and the film was
used as a template to excise slices of polyvinyldifluoride membranes con-
taining the desired species. Polyvinyldifluoride slices were loaded directly
to a Gas-Phase Sequencer (model 470; Applied Biosystems, Inc., Foster
City, CA). A 150-ml sample from each sequencing cycle containing phenyl-
thiohydantoin (PTH)-derivatized amino acids was added to 5 ml scintilla-
tion fluid, and the radioactivity of the [35S]PTH-methionine, [3H]PTH-
proline, or [3H]PTH-lysine was counted in ASC2 scintillation fluid in a liq-
uid scintillation counter. A background value, established by counting a
blank sample, was subtracted from the total counts that were determined
for each sequencing sample.
Cell Fractionation
10 OD600 U of yeast cells were labeled with 300 mCi [35S]cysteine for 5 min
in SD media with appropriate supplements. Labeled cells were washed
once in cold distilled H2O and resuspended in 100 ml cell fractionation
buffer (50 mM potassium phosphate, pH 7.4, 150 mM NaCl, 1 mM b-mer-
captoethanol, 1 mM PMSF, and 0.5% Trasylol). Cells were disrupted with
zirconium beads by vortexing six times in 1-min bursts at 48C, the crude
extract was transferred into a new tube, and cellular debris was removed
by centrifugation at 1,000 g for 10 min. This supernatant is designated the
total cellular extract (T). To determine the nature of the association of
a-factor with the membrane, the T extract was incubated at 48C for 15 min
alone or in the presence of one of the following compounds: 0.5% Triton
X-100, 0.1 M Na2CO3, pH 12.5, 1.6 M urea, or 2 M NaCl. The treated ex-
tract was centrifuged at 100,000 g for 1 h; the supernatant was designated
the soluble fraction (S). The protein in the S fraction was concentrated by
TCA precipitation, resuspended in 30 ml 23 Laemmli sample buffer, and
neutralized with 2.0 M Tris base. The 100,000 g pellet, designated the par-
ticulate fraction (P), was washed once with cold cell fractionation buffer
and resuspended in 30 ml 23 Laemmli sample buffer. The T, S, and P frac-
tions were subjected to immunoprecipitation and SDS-PAGE, as de-
scribed above. An equivalent amount of each fraction, normalized accord-
ing to the OD600 U, was loaded in each lane on SDS-PAGE.
Quantitative Analysis of a-Factor Biosynthesis
Dried gels from pulse-chase experiments were exposed to a Molecular
Dynamics Phosphor Screen for several days, and the resulting data were
quantified using Molecular Dynamics Image Quant software.
The identity of the intracellular precursor (P1 and P2) species and of
mature (M) a-factor are shown in Fig. 5. M(I) and M(E) refer to intracel-
lular and extracellular mature a-factor, respectively. The “processing effi-
ciency” shown in Table III refers to the percentage of a-factor precursor
initially synthesized [P11P2]09 that is ultimately proteolytically cleaved to
the M form [M(I)1M(E)]159. The time point of 15-min chase was chosen
because the level of the total M form does not increase after this time. The
processing efficiency is calculated by the following formula:
The “export efficiency” shown in Table III indicates the fraction of the
total intracellular a-factor initially synthesized at T09 [P11P21M(I)]09 that
is ultimately exported to the culture fluid after secretion is complete
[M(E)]309, expressed as a percentage. The export efficiency is calculated
by the following formula:
The precise half-time (t1/2) of a-factor export is complex to measure,
since the data indicates that there are two separate rates for this process,
an initial rapid rate followed by a slow rate. We observe here that 80% of
export is completed by 15 min of chase.
Examining a-Factor Biosynthesis After
a-Factor Induction
10 OD600 U of log-phase MATa cells (SM1227) were resuspended in SD
media plus the appropriate supplements. 2 OD600 U of cells were immedi-
ately set aside as an untreated control sample. Synthetic a-factor (Sigma
Immunochemicals, St. Louis, MO) was added to the remaining 8 OD600 U
processing efficiency  % ()
MI () ME () + [] 159
P1 P2 + [] 0 9
-------------------------------------------------- 100 ´ =
export efficiency  % ()
ME () 309
P1 P2 M I () + + [] 0 9
----------------------------------------------------- 100 ´ =
of cells to a final concentration of 25 mM, and a-factor–treated cells were
incubated at 308C. At various time points after the a-factor addition, ali-
quots (2 OD600 U) were metabolically labeled with 150 mCi [35S]cysteine
for 5 min followed by a 45-min chase. Control cells were labeled the same
way, except in the absence of a-factor. The I fraction was prepared from
half of the pulse-labeled cells, whereas the E fraction was prepared from
the remaining half of the culture that had completed the chase. I and E
fractions were immunoprecipitated with a-factor antiserum and subjected
to SDS-PAGE analysis. The data were quantitated by Phosphorimager
analysis.
Results
Identification of a-Factor Biosynthetic Intermediates
As a first step in characterizing the a-factor biogenesis
pathway, we used metabolic labeling to identify a-factor
biosynthetic intermediates. Cells were radiolabeled with
[35S]cysteine under steady-state conditions. Intracellular
and extracellular species of a-factor were immunoprecipi-
tated with a-factor antiserum. The immunoprecipitates
were analyzed by a modified SDS-PAGE procedure (see
Materials and Methods) that was optimized for the separa-
tion of a-factor intermediates. Because of their unusually
small size, a-factor and its biosynthetic intermediates are
difficult to resolve by standard SDS-PAGE techniques.
Fig. 2 shows the pattern of a-factor biosynthetic species
generated in a strain carrying a single a-factor gene MFA1.
In the intracellular fraction (Fig. 2, lane 4), three species
are apparent, two that are precursor sized, P1 and P2, and
one that is mature sized, M. In the extracellular fraction
(Fig. 2, lane 5), only mature a-factor is observed. Whereas
the three intracellular species (P1, P2, and M) are present
in cells carrying an a-factor gene (MFA1; Fig. 2, lanes 4
and 5), they are absent in an a-factor null mutant strain
(Dmfa1 Dmfa2; lanes 2 and 3), and can be competed away
by inclusion of an excess of cold a-factor synthetic peptide
(lanes 6 and 7) in the immunoprecipitation. Thus, P1, P2,
and M appear to be authentic MFA1-derived a-factor spe-
cies. Analogous gel bands are also present in strains ex-
pressing solely MFA2 (see Fig. 8). The P1 and P2 a-factor
species migrate between the 3- and 6-kD molecular mass
standards, compatible with the predicted molecular mass
(z4.5 kD) for the a-factor precursor. M migrates at a posi-
tion near to that of the 3-kD marker. This is somewhat
slower than predicted for mature a-factor (1.6 kD), per-
haps caused in part by the hydrophobicity of a-factor.
For comparison, the in vitro transcribed and translated
product derived from the MFA1 gene was immunoprecipi-
tated and analyzed by SDS-PAGE. Two slowly migrating
species are apparent (Fig. 2, lane 1). The species with the
lowest mobility (marked by an asterisk) most likely corre-
sponds to the primary a-factor translation product, P0. It
should be noted that the P0 form of the a-factor precursor
cannot generally be detected in vivo under steady-state la-
beling conditions, probably because of its rapid conversion
to P1 (thus, it is absent in Fig. 2, lane 4); however, P0 can be
detected in vivo after a short pulse label (see Fig. 5) or
when a-factor farnesylation is blocked by a CAAX mutation
(Fig. 6) or by farnesyltransferase mutations (ram1 or ram2;
He et al., 1991). The higher mobility a-factor species present
in Fig. 2, lane 1 likely corresponds to the partially or fully
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ing from prenyltransferase activity and possibly protease
activity present in the wheat germ translation extract.
P1, P2, and M are COOH-terminally
Modified Intermediates
We wished to directly determine the COOH-terminal
modification status of the intermediates observed in Fig. 2.
Because methylation is obligatorily the last step in the
COOH-terminal modification of CAAX proteins, it can
be used as a marker for the completion of a-factor COOH-
terminal processing (Hrycyna and Clarke, 1992). To deter-
mine whether the a-factor biosynthetic intermediates P1,
P2, and M are methylated, a MATa strain carrying a plas-
mid-borne wild-type MFA1 gene was double labeled with
the methyl group donor [3H]methyl AdoMet and [35S]cys-
teine. We also examined in parallel a strain carrying a plas-
mid-borne CAAX mutant, mfa1-C33S. Since the mfa1-
C33S CAAX mutation blocks the farnesylation of a-factor
(Chen, 1993), it will also prevent AAX cleavage and meth-
ylation. Intracellular a-factor was immunoprecipitated,
and biosynthetic intermediates were separated by SDS-
PAGE. After visualization by autoradiography, 35S-labeled
bands corresponding to P0, P1, P2, and M were excised
from the gel and the extent of methylation of each species
was determined by the vapor phase equilibrium assay
(Clarke et al., 1988; Hrycyna et al., 1991). This assay spe-
cifically detects ester-linked methyl groups, which are lib-
erated as [3H]methanol after base hydrolysis (see Materi-
Figure 2. Identification of a-factor biosynthetic intermediates.
Cells were labeled with [35S]cysteine under steady-state condi-
tions and intracellular (I) and extracellular (E) extracts were pre-
pared. Proteins were immunoprecipitated with a-factor antiserum
(Ab-9-137), separated by 16% SDS-PAGE, and visualized by au-
toradiography, as described in Materials and Methods. The in
vitro precursor (IVP; lane 1) was generated by transcription and
translation of MFA1 from pSM118. Strains are transformants of an
a-factor deletion strain (Dmfa1 Dmfa2) and contain either no
plasmid (lanes 2 and 3; SM1458) or an a-factor plasmid, pSM464
(CEN MFA1; lanes 4–7; SM1829). In the peptide competition ex-
periment (lanes 6 and 7), the labeled extracts are the same as in
lanes 4 and 5, respectively, except that a 50-fold excess of cold
synthetic dodecapeptide (YIIKGVFWDPAC) corresponding to
mature  a-factor was added before immunoprecipitation. The
a-factor precursor species are designated P1 and P2, and the
band corresponding to mature a-factor is designated M. Molecu-
lar mass markers are indicated. The band in lane 1 just above P1,
marked by an asterisk, most likely represents the unmodified
a-factor precursor P0.
Figure 3. Carboxyl methylation assay to determine the COOH-
terminal modification status of a-factor biosynthetic intermedi-
ates. The methylation status of a-factor biosynthetic intermedi-
ates was determined in a strain containing a wild-type MFA1
plasmid (A, SM1585) or a plasmid with the a-factor CAAX muta-
tion  mfa1-C33S (B, SM1682), in which prenylation and subse-
quent modification of a-factor is prevented. Cells were double la-
beled with [35S]cysteine and [3H-methyl]AdoMet (A) or with
Trans35-label and [3H-methyl]AdoMet (B), respectively. Cell ex-
tracts were prepared, proteins were immunoprecipitated with
a-factor antibodies, separated by 16% SDS-PAGE, and the dried
gel was subjected to autoradiography to detect the indicated in-
tracellular a-factor biosynthetic intermediates. Each a-factor in-
termediate was excised from the gel, and the relative degree of
carboxyl methylation was determined. Incorporation of 3H into
methyl esters was determined by subjecting the excised gel slice
to the vapor phase equilibrium assay in which 3H-labeled methyl
ester groups are converted to [3H]methanol counts. Total 35S in-
corporation was determined by solubilization of the gel slice. The
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als and Methods). The ratio between 3H and 35S for each
species reflects its relative level of methylation.
The P1, P2, and M species derived from wild-type
MFA1 all contain COOH-terminal methyl esters, as evi-
denced by the presence of [3H]methanol counts (Fig. 3 A).
Conversely, the P0 species synthesized by the mfa1-C33S
CAAX mutant lacks methylation, as expected (Fig. 3 B).
This experiment demonstrates that all of the wild-type
a-factor biosynthetic intermediates (P1, P2, and M) are
methylated and thus have undergone complete COOH-
terminal modification. It is likely that the differences in
the apparent extent of methylation of the three species, as
defined by their 3H/35S ratios, is caused in part by the over-
expression of MFA1, and resultant incomplete methyla-
tion of P1 in the experiment shown in Fig. 3. In a similar
experiment in which MFA1 was expressed from a low
copy number CEN plasmid, the 3H/35S ratios of P1, P2, and
M were closer to one another (P1 and P2 differed by only
1.3-fold; P2 and M were equivalent; data not shown).
These results suggest that at chromosomal levels of ex-
pression, the relative extent of methylation for the P1, P2,
and M species are likely to be identical. Since P1, P2, and
M have all completed COOH-terminal modification, their
differing SDS-PAGE mobilities must reflect differences in
their NH2-terminal processing status.
P1 Has an Intact NH2-terminal Extension, P2 Has a 
Partially Processed NH2-terminal Extension, and M Is 
Fully Processed
To further define the structure of the a-factor biosynthetic
intermediates, we determined the NH2-terminal amino
acid of each a-factor species by radiolabeled peptide se-
quence analysis (Fig. 4). An a-factor deletion strain carry-
ing wild-type MFA1 on a high copy number plasmid was
labeled with [3H]lysine or [3H]proline (Fig. 4, A and B,
respectively). Radiolabeled a-factor intermediates were
separated by SDS-PAGE, followed by blotting onto a poly-
vinyldifluoride membrane. Excised segments of the polyvi-
nyldifluoride membrane containing a single a-factor species
were subjected to automated gas phase Edman degrada-
tion analysis. In addition to strains carrying wild-type MFA1,
a strain carrying a mutant plasmid, mfa1-I23M, which con-
tains an engineered methionine codon within the mature
portion of a-factor, was labeled with [35S]methionine and
analyzed (Fig. 4 C). This mutant was included for analysis
because the higher energy of 35S as compared to 3H per-
mitted optimal detection of radiolabeled residues. The
amount of extracellular a-factor produced by mfa1-I23M is
comparable to that of wild-type, indicating that a-factor
maturation and secretion are relatively normal for the mu-
tant (Nouvet, F., and S. Michaelis, unpublished observation).
When the [3H]lysine-labeled P1 species was subjected to
Edman degradation, peaks of radioactivity were detected
in cycles 11 and 13 (Fig. 4 A). This is the result expected if
P1 begins with the first methionine of the a-factor precur-
sor. It should be noted that the apparent “trailing” of a
peak into a succeeding cycle (as seen here in cycle 11 trail-
ing into 12, and 13 into 14) is not uncommon with this
technique, and occurs when the degradation within a par-
ticular cycle is incomplete. For [3H]proline-labeled P1, dis-
tinct peaks of radioactivity are detected in cycles 3 and 10
(Fig. 4 B), and for [35S]methionine-labeled P1, produced
from the I23M mutant a-factor, peaks are detected in cy-
cles 1 and 23 (Fig. 4 C). Taken together, these results indi-
cate that the P1 species of a-factor contains an intact NH2-
terminal extension.
We next determined the NH2-terminal sequence of P2.
For [3H]lysine-labeled P2, peaks are present in cycles 4
and 6 (Fig. 4 A). This result is consistent with the NH2-
terminal residue of P2 coinciding with residue A8 of the
a-factor precursor, as indicated by the designation “P1®P2
cleavage site” in Fig. 4, A and B. The identity of the NH2-
terminal residue of P2 as A8 was further confirmed by
analysis of [3H]proline labeled P2, in which a peak is
present in cycle 3 (Fig. 4 B). Thus, rather unexpectedly,
the P2 species appears to be the product of an unpredicted
proteolytic cleavage step within the NH2-terminal exten-
sion of the a-factor precursor; such an intermediate was
not anticipated a priori from our previous knowledge of
the sequence of precursor and mature forms of a-factor.
A somewhat different result was obtained upon se-
quence analysis of the [35S]methionine-labeled P2 species
derived from the I23M mutant. Peaks were detected both
in cycles 16 and 18 (Fig. 4 C), suggesting that in this mu-
tant, P2 actually consists of two species, one beginning
at residue A6 and the other at A8. The I23M version of
a-factor may undergo an aberrant processing reaction, in
which an anomalous cleavage occurs between residues T5
and A6 in addition to the normal cleavage between T7 and
A8. Alternatively, it is possible that there is a very minor
cleavage site between T5 and A6, even for the wild-type
precursor, and that this site is used more efficiently by the
mutant. It is not clear why the I23M mutation, which is
quite distant from the P2 cleavage site, has an effect on the
P1®P2 conversion. Interestingly, we have found that an-
other mfa1 mutation near this region, I24N, also has an ef-
fect on this processing step, resulting in a slower than nor-
mal rate of P1®P2 conversion (Nouvet, F., A. Kistler, and
S. Michaelis, manuscript in preparation).
We also investigated the NH2-terminal sequence of the
intracellular mature species, M. For [3H]lysine-labeled M,
radioactivity was recovered in cycle 4 (Fig. 4 A). Corre-
spondingly, for [35S]methionine-labeled M derived from
the I23M mutant, radioactivity was recovered in cycle 2
(Fig. 4 C). (The [3H]proline signal for M was too low to
count.) These results indicate that intracellular M has the
same NH2 terminus (Y22) as that previously established
for extracellular M by mass spectrometry (Anderegg et al.,
1988); thus, intracellular M has undergone complete re-
moval of the NH2-terminal extension.
In summary, NH2-terminal radiolabeled peptide sequence
analysis (Fig. 4), in combination with the assessment of the
carboxyl methylation status (Fig. 3) of the a-factor inter-
mediates, indicates that their structure is as follows (Fig. 5):
P0 is the unmodified, full-length a-factor precursor; P1 is
the COOH-terminally modified precursor with an intact
NH2-terminal extension; P2 is generated by a proteolytic
cleavage step within the NH2-terminal extension, which
removes seven amino acids; and M represents COOH-ter-
minally modified, mature a-factor with its NH2-terminal
extension completely removed. It is notable that this analysis
revealed a novel precursor species, P2, which was not pre-
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P1, P2, and M All Behave as Peripheral
Membrane Proteins
Prenylation is necessary but not sufficient to mediate the
membrane localization of at least several CAAX proteins
(Hancock et al., 1990). To determine whether a-factor in-
termediates are soluble or membrane-bound when preny-
lation is prevented by an a-factor CAAX mutation, cells
were labeled with [35S]cysteine, and the total cellular ex-
tract (T) was separated into particulate (P) and soluble (S)
fractions by centrifugation at 100,000 g. We examined a
wild-type strain and strains that could not carry out preny-
lation, including two different a-factor CAAX mutants
(mfa1-DVIA and mfa1-C33S) and a ram1 mutant that we
had analyzed previously (He et al., 1991). As shown in Fig.
6 A, the mutant strains synthesize exclusively P0, which
fails to reach the membrane (Fig. 6 A, lanes 4–6, 7–9, and
10–12). In contrast, in cells bearing wild-type MFA1, all
the a-factor intermediates, P1, P2, and M, are mainly de-
Figure 4. Radiolabeled pep-
tide sequence analysis to es-
tablish the NH2-terminal
processing status of intracel-
lular species of a-factor. The
a-factor species in immuno-
precipitates from cells la-
beled with [3H]lysine (A),
[3H]proline (B), or Trans35S
label (methionine:cysteine 5
20:1) (C) were separated by
16% SDS-PAGE and trans-
ferred onto polyvinyldifluo-
ride membrane. The intracel-
lular  a-factor intermediates
P1, P2, and M were visual-
ized by autoradiography, ex-
cised, and subjected to Ed-
man degradation analysis.
The radioactive material
from each cycle was quanti-
tated by scintillation count-
ing as shown in the bar
graph. Within the a-factor se-
quence, the radiolabeled
amino acid used for labeling
is shaded darkly, and the de-
duced P1®P2 and P2®M
cleavage sites are indicated.
The strain labeled in A and B
is SM1762, which carries the
wild-type  a-factor plasmid
pSM463 (2m MFA1). The
strain labeled in C is SM1932,
which harbors an a-factor
substitution mutant plasmid,
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tected in the particulate (P) fraction (Fig. 6 A, lanes 1–3),
suggesting that all of these species are membrane associ-
ated.
To further examine the nature of a-factor membrane
association, the total cellular lysate was subjected to a va-
riety of extraction conditions before centrifugation (Fig.
6 B). The nonionic detergent Triton X-100 efficiently solu-
bilizes a-factor (Fig. 6 B, lanes 4–5), presumably because
of the disruption of membrane structure. a-Factor was also
solubilized by treatment with 0.1 M Na2CO3, pH 12.5 (Fig.
6 B, lanes 6 and 7). Since 0.1 M Na2CO3 normally only re-
leases peripheral membrane proteins (Fujiki et al., 1982),
this result suggests that a-factor does not behave as an in-
tegral membrane protein. a-Factor was not solubilized by
1.6 M urea (Fig. 6 B, lanes 8 and 9) nor by 1 M NaCl (Fig.
6 B, lanes 10 and 11), suggesting that, in contrast to typical
peripheral membrane proteins, ionic interactions are not
critical for a-factor membrane association. For the most
part, all the a-factor intermediates exhibit similar fraction-
ation and extraction properties, suggesting a common
mechanism for their membrane association. More detailed
subcellular fractionation analysis is needed to determine
whether the different species of a-factor are localized to
the same or to distinct membrane compartment(s).
COOH-terminal Prenylation Precedes and Is Obligatory 
for the NH2-terminal Processing of a-Factor
Having established the identity and fractionation proper-
ties of the a-factor biosynthetic intermediates, we next ad-
Figure 5. The deduced struc-
ture of a-factor intermedi-
ates. The SDS-PAGE analy-
sis of immunoprecipitated
intracellular (I) and extra-
cellular (E) species of a-fac-
tor present after a brief (5-
min) pulse labeling is shown
(right). The deduced struc-
ture of each a-factor biosyn-
thetic intermediate is indi-
cated (left), based on the
results from the carboxyl
methylation assay (Fig. 3)
and the radiolabeled peptide
sequence analysis (Fig. 4).
The strain labeled is SM1710,
which contains pSM233
(CEN MFA1).
Figure 6. Fractionation and solubilization properties of intracel-
lular a-factor. In A, cells were labeled with [35S]cysteine for 5 min
and lysates were prepared. The total cellular lysate (T) was sepa-
rated into particulate (P) and soluble (S) fractions by centrifu-
gation at 100,000 g for 1 h at 48C. The a-factor species were im-
munoprecipitated and subjected to SDS-PAGE analysis. Strains
examined in lanes 1–9 (SM1585, SM1682, and SM1680) carry either
a wild-type or mutant MFA1 plasmid, as indicated. Strain SM1865,
examined in lanes 10–12, is a Dram1 mutant. In B, a strain con-
taining a wild-type MFA1 plasmid (SM1762) was labeled with
[35S]cysteine for 5 min. The total lysate (T) was subjected to the
indicated treatments or to no treatment (control, lanes 1–3) and
subsequently separated into particulate (P) and soluble (S) frac-
tions by centrifugation at 100,000 g for 1 h at 48C. The a-factor in-
termediates were immunoprecipitated and analyzed by SDS-
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dressed the order of a-factor maturation events. Does
COOH-terminal modification occur first, followed by NH2-
terminal processing, or vice versa? The answer is evident
by inspection of Fig. 6 A, which provides a comparison of
a-factor biogenesis profiles under conditions when preny-
lation of the a-factor precursor does or does not occur.
When prenylation is blocked, either because of an a-factor
CAAX mutation, mfa1-DVIA or C33S (Fig. 6 A, lanes 4
and 7), or because of a defective prenylation enzyme
(ram1; Fig. 6 A, lane 10), only a single species of a-factor
(P0) is generated. In contrast, three species (P1, P2, and
M) are evident for wild-type MFA1 (Fig. 6 A, lane 1). The
absence of the NH2-terminally cleaved intermediates, P2
and M, in the prenylation mutants indicates that prenyla-
tion is a prerequisite step in a-factor biogenesis, without
which further NH2-terminal processing does not occur.
We also examined the order of appearance of P1 and P2
in a wild-type strain (Fig. 7). If NH2-terminal processing is
contingent upon COOH-terminal prenylation, then we
would expect that in a pulse-chase experiment, P2 would
appear only after the formation of P1. Indeed, in a very
brief (1-min) pulse labeling experiment, P2 becomes ap-
parent only after 2–4 min of chase, whereas P1 is present
at the very earliest chase time. By 8 min, about half of the
P1 synthesized has been converted to P2, and further
P1®P2 conversion stops. These data are consistent with
the results from the prenylation mutants, which indicate
that COOH-terminal prenylation is required for the NH2-
terminal processing of a-factor.
Kinetic Analysis of a-Factor Biogenesis in Strains 
Expressing Chromosomal MFA1 or MFA2: P2®M 
Conversion Occurs at Low Efficiency
To obtain an overall view of a-factor biogenesis, we con-
ducted pulse-chase experiments using strains expressing
Figure 7. Kinetic analysis demonstrating P1®P2 conversion of
the a-factor precursor. Strain SM1762, which carries pSM463
(2m MFA1), was pulse labeled with [35S]cysteine for 30 s, chased
for the indicated time points (in minutes), and extracts were pre-
pared. The intracellular fraction was subjected to immunoprecip-
itation, SDS-PAGE, and autoradiography.
Figure 8. Kinetic analysis of
a-factor biogenesis in strains
expressing MFA1 or MFA2
at low (chromosomal), inter-
mediate (CEN), or high (2m)
levels. Cells were pulse la-
beled with [35S]cysteine for 5
min, and the label was chased
for the times indicated. Intra-
cellular (I) and extracellular
(E) fractions were prepared,
and proteins were subjected
to immunoprecipitation, SDS-
PAGE, and exposed to a
Phosphorimager screen for
24 h. The P1, P2, and M spe-
cies are indicated. A constant
gray scale value is used for all
the scans shown, so that the
relative level of a-factor spe-
cies in each strain can be
qualitatively compared by di-
rect visual inspection. The
strains examined here ex-
press  MFA1 or MFA2 only,
from the chromosome
(SM2892 and SM3019), a
CEN plasmid (SM2891 and
SM3020), and a 2m plasmid
(SM2893 or SM3021).The Journal of Cell Biology, Volume 136, 1997 262
either MFA1 or MFA2 from the chromosome. Cells were
pulse labeled with [35S]cysteine for 5 min, subjected to a
chase for up to 60 min, and samples from several time
points were immunoprecipitated and analyzed by SDS-
PAGE (Fig. 8 A). The data was quantified by phosphorim-
ager analysis and was used to quantitate two parameters of
a-factor biogenesis (Table III): One parameter is desig-
nated processing efficiency and measures the percentage
of mature a-factor, both intracellular M(I) and extracellu-
lar M(E), that is formed relative to the total amount of
a-factor synthesized in a 5-min pulse. The second parame-
ter is designated overall export efficiency and it measures
the fraction of mature a-factor that is ultimately secreted
to the extracellular culture fluid, relative to the total
amount of a-factor synthesized. As discussed below, our
measurements (Table III) suggest an inherent inefficiency
in particular steps of the a-factor biogenesis pathway.
In general, the a-factor precursors encoded by the chro-
mosomal MFA1 and MFA2 genes exhibit properties of
maturation and export that are similar to one another (Fig.
8 A), although the total amount of a-factor produced from
the chromosomal MFA2 gene is significantly less (by
about threefold) than for MFA1. Another difference be-
tween MFA1- and MFA2-encoded a-factor is that only the
P2 precursor, and not P1, can be detected for chromo-
somal MFA2 (Fig. 8 A). Most likely, the absence of P1 for
chromosomally expressed MFA2 simply reflects the rapid
and quantitative P1®P2 conversion that occurs when the
total amount of a-factor synthesized is low. When the
MFA2 level is increased by expression from CEN and 2m
plasmids, the MFA2 P1 species becomes apparent (Fig. 8,
B and C).
A striking feature apparent from the kinetic analysis of
chromosomally expressed a-factor (Fig. 8 A) is that the
overall export efficiency is surprisingly low. Less than 15%
of the total amount of a-factor synthesized in a 5-min pulse
(8% for MFA1 and 14% for MFA2, Table III) ever ap-
pears as mature a-factor in the culture fluid, even after ex-
port is essentially complete. What step(s) of a-factor bio-
genesis can account for this low level of efficiency? Visual
inspection of the a-factor biogenesis gel profile (Fig. 8 A,
also B and C) reveals that P2 is an abundant species,
whereas only a modest amount of mature a-factor is gen-
erated. Quantitation of the processing efficiency confirms
that only a small portion of the precursor initially synthe-
sized is ultimately converted to mature a-factor (11% for
MFA1, 30% for MFA2; Table III). Thus, the P2®M NH2-
terminal processing step appears to be the least efficient,
and as a result, the rate-limiting step in a-factor biogenesis;
therefore, this is the step at which regulation, if it exists,
would most likely be imposed. An additional factor that
contributes to the low overall export efficiency of a-factor
is that only about half of the intracellular M(I) that is gen-
erated is actually secreted to become extracellular M(E)
(Fig. 8 A). The remaining intracellular M(I) simply re-
mains inside the cell. It is not clear why the entire pool of
intracellular mature a-factor is not capable of being ex-
ported.
Processing and Biogenesis of a-Factor Is Similar among 
Unrelated Strains of S. cerevisiae
To ensure that the low processing and biogenesis effi-
ciency we observe is not caused by a peculiarity of our
strain background, we examined a-factor biosynthesis in
yeast strains derived from distinct genetic lineages. We
compared the a-factor biogenesis profiles of three widely
used S. cerevisiae strains: S288C (Mortimer and Johnston,
1986), SK1 (Alani et al., 1987), and S1278B (Brandriss
and Magasanik, 1979) to that of SM1058 (also known as
EG123 [Siliciano and Tatchell, 1984]), which is our main
laboratory strain and is itself derived from S288C. Cells
were pulse labeled with [35S]cysteine and were processed
with or without a chase to examine the amount of a-factor
initially synthesized, as well as the percentage of a-factor
that is processed and exported to the culture fluid. The sta-
tus of intracellular and extracellular a-factor was analyzed
by immunoprecipitation, SDS-PAGE, and Phosphorim-
ager analysis (Fig. 9). The overall pattern observed in each
strain is the preponderance of precursor species (P1 and
P2) versus mature a-factor (M), just as in our strain,
SM1058. Thus, the conversion of the a-factor precursor
into mature a-factor appears to be inefficient in all of the
strains tested.
Figure 9. Comparison of the overall a-factor biogenesis pattern
in yeast strains derived from distinct genetic lineages. Strains
SM1058, S288C, SK-1, and S1278B were pulse labeled with
[35S]cysteine for 5 min. Intracellular (I) and extracellular (E)
a-factor species were immunoprecipitated immediately or after a
15-min chase and analyzed by SDS-PAGE and autoradiography.
Table III. Processing Efficiency and Overall Export Efficiency 
of a-Factor
Processing
efficiency*‡
Export
efficiency*§
MFA1 11% 8%
MFA2 30% 14%
*Values were calculated from cells expressing chromosomal MFA1 or MFA2 only
(SM2891 and SM2892, respectively) and are averaged from Phosphorimager analysis
of two gels, one of which is shown in Fig. 8 A. The calculations are based on the as-
sumption that each a-factor molecule contains only a single radiolabeled residue
([35S]cysteine). Even if some metabolic conversion of [35S]cysteine to [35S]methionine
could occur, the overall values would not be altered significantly; only P1, which con-
tains an NH2-terminal Met, would be affected.
‡The “processing efficiency” is the percentage of a-factor precursor that is initially
synthesized within a 5-min pulse [P1 1 P2]09 that is ultimately converted after 15 min
to mature a-factor [M(I) 1 M(E)]159.
§The “export efficiency” is the percentage of a-factor initially synthesized [P1 1 P2 1
M(I) 1 M(E)]09 that is ultimately exported to culture fluid as mature a-factor [M(E)]309.Chen et al. Biogenesis of Yeast a-Factor 263
Expression of Increasing Amounts of a-Factor Results 
in a Back-Up at the P1®P2 Processing Step
To determine whether the overall pattern of maturation or
export is altered when a-factor is overexpressed, we exam-
ined  a-factor biogenesis in strains expressing chromo-
somal,  CEN, and 2m MFA1 or MFA2. Overall, as can be
seen in Fig. 8, A–C, very few differences are apparent be-
tween MFA1- and MFA2-encoded a-factor (with the ex-
ception that P1 is difficult to discern for chromosomal
MFA2). Because of their overall similarity, further quanti-
tation is reported for MFA1 only. For quantitation, sam-
ples from strains expressing increasing levels of MFA1
were compared on a single gel (Fig. 10 A). The total
amount of a-factor synthesized in each case was deter-
mined. For CEN and 2m MFA1 plasmids, the total amount
of a-factor synthesized is 4- and 10-fold greater, respec-
tively, than for chromosomal MFA1. The fourfold increase
for  CEN MFA1 versus chromosomal MFA1 is in good
agreement with the heightened level of expression we
have observed for other genes (e.g., STE6, STE14) cloned
into CEN vectors, and is consistent with the notion that
the copy number of these CEN plasmids is greater than
one per cell.
Strikingly, as a-factor production increases, the level of
P1 increases disproportionately to that of other species
(Fig. 10 A); whereas the species P2, M(I), and M(E) each
undergo a modest increase in level (of about two- to four-
fold as copy number increases from chromosomal to 2m
MFA1), P1 accumulates to extremely high levels (23-fold;
Fig. 10 B). Thus, when expression of a-factor is relatively
low, it is the inherent inefficiency of the P2®M processing
step that limits the amount of mature a-factor that can be
generated. When a-factor is overexpressed, however, a
more severe bottleneck develops at the preceding NH2-
terminal processing step (P1®P2), resulting in the accu-
mulation of a disproportionately high level of P1. Hence,
both of the a-factor NH2-terminal processing steps, P1®P2
and P2®M, have the capacity to serve as potential points
of regulation to limit (or increase) the amount of mature
a-factor available for export.
a-Factor Induction Does Not Affect the Processing or 
Export Efficiency of a-Factor
The transcription of many genes involved in mating, in-
cluding MFA1 and MFA2, is stimulated upon pheromone
treatment (Sprague and Thorner, 1992). To examine whether
any steps in the a-factor biosynthetic pathway are specifi-
cally affected by a-factor induction, we incubated cells
with a-factor for varying lengths of time, and carried out
metabolic labeling and immunoprecipitation of a-factor, as
described in Materials and Methods. As can be seen in Fig.
11, within 5 min after treatment with a-factor, we detected
a significant increase in the overall level a-factor produc-
Figure 10. Comparison of the a-factor biosynthesis profile in
strains expressing MFA1 at low (chromosomal), intermediate
(CEN), or high (2m) levels. To quantitate the total amount of
precursor plus mature a-factor synthesized in each of the MFA1-
bearing strains shown in Fig. 8, and to determine the relative
amounts of each a-factor intermediate, the intracellular immuno-
precipitates from the 0-min chase time point and the extracellular
immunoprecipitates from the 15-min chase point shown in Fig. 8
were electrophoresed side by side and quantitated by Phosphor-
imager analysis. A shows the Phosphorimager scan. B shows the
quantitation of a-factor intermediates from A. Values are ex-
pressed relative to chromosomal intracellular mature a-factor,
M(I), which is set at 1.0. M(E) refers to extracellular mature
a-factor. These data illustrate two points: the low level of mature
(M(I) 1 M(E)) relative to precursor species, indicative of the low
efficiency of P2®M processing, and the buildup of P1 when
a-factor is expressed at very high levels.
Figure 11. Examination of a-factor biogenesis after a-factor in-
duction. Strain SM1227 (MFA1 mfa2::URA3) was preincubated
with 25 mM a-factor (except for the 0-min sample). At the indi-
cated times, which represent minutes after the addition of phero-
mone, cells were pulse labeled with [35S]cysteine for 5 min, and
the label was chased for 45 min. (For the 0-min control sample,
the pulse chase was carried out in the absence of any a-factor.)
The intracellular (I) fraction was prepared from a portion of the
5-min pulse-labeled cells to examine the total amount of a-factor
synthesized, and the extracellular (E) fraction was prepared from
an equivalent portion of the culture that had completed the 45-min
chase to examine the portion of the a-factor synthesized in the
pulse that ultimately underwent maturation and export. Fractions
were immunoprecipitated with a-factor antiserum and subjected
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tion (Fig. 11, lane 1 vs. lane 2). The induction reached its
peak 30 min after a-factor addition (Fig. 11, lane 3) and
a-factor production returned to its lower constitutive level
by 90 min (Fig. 11, lane 4). Quantitative analysis (data not
shown) revealed that both the precursor (P1 and P2) and
mature (M) species of a-factor were elevated to a compa-
rable level at each time point (about fivefold at 30 min).
However, neither “processing efficiency” nor the “export
efficiency” appear to vary upon a-factor treatment. Thus,
the increase in extracellular a-factor after induction (Fig.
11, lane 1 vs. lane 3) is caused primarily by the heightened
expression of the a-factor genes, rather than by any alter-
ation of the a-factor processing or biogenesis efficiency.
Therefore, it does not appear to be the case that the excess
intracellular pool of a-factor precursor becomes “recruited”
after pheromone induction.
Discussion
The maturation and secretion of the yeast mating phero-
mone a-factor represents a novel paradigm for the biogen-
esis of a secreted signaling molecule. In the present study,
we wished to elucidate the major events of the a-factor
biogenesis pathway by characterizing a-factor biosynthetic
intermediates. Using metabolic labeling, immunoprecipi-
tation, and SDS-PAGE analysis, we identified four distinct
a-factor intermediates (Fig. 2), determined the structure of
these species (Fig. 5), including the COOH-terminal modi-
fication status and NH2-terminal residue of each (Figs. 3
and 4, respectively), examined their membrane association
(Fig. 6 B), and determined their order of formation with
respect to COOH- and NH2-terminal processing events
(Fig. 6 A). A notable insight that emerged from this analy-
sis was the identification of an unanticipated a-factor bio-
synthetic intermediate, P2, in which a portion of the NH2-
terminal extension of the a-factor precursor (the first 7 of
21 residues) is removed, presumably by a specific endo-
protease. The existence of this novel partially NH2-termi-
nally processed a-factor intermediate predicts that not just
one, but two NH2-terminal cleavage steps occur during
a-factor biogenesis.
A Model for a-Factor Biogenesis
The identification of a-factor biosynthetic intermediates
carried out here, together with other studies identifying
components of the a-factor maturation and export ma-
chinery, allow us to formulate a working model for the
a-factor biogenesis pathway (Fig. 12). The precursor and
mature species of a-factor that we characterized in this
study are presented together with the cellular components
that are postulated to mediate their formation. According
to our model, the unmodified a-factor precursor (P0) first
undergoes COOH-terminal modification (prenylation, pro-
teolytic trimming, and carboxyl methylation) mediated by
Ram1p/Ram2p (He et al., 1991; Schafer et al., 1990), the
AAX protease (Ashby et al., 1992; Hrycyna and Clarke,
1992), and Ste14p (Hrycyna et al., 1991; Sapperstein et al.,
1994), respectively, to yield the fully COOH-terminally
modified and membrane associated precursor (P1). (It
should be noted that our analysis has not identified dis-
tinct COOH-terminal intermediates that are only partly
modified, either because their formation and disappear-
ance is very rapid or because they do not exhibit distinc-
tive mobilities in our gel system.) Subsequent to the com-
pletion of COOH-terminal modification, NH2-terminal
proteolytic processing occurs and appears to involve two
sequential steps. The first NH2-terminal cleavage event is
the unanticipated processing step uncovered by this study,
which generates the NH2-terminally “clipped” intermedi-
ate (P2); we provide evidence elsewhere that formation of
P2 is dependent on the Ste24p protease (Fujimura-Kamada
et al., 1997). The second NH2-terminal processing event is
Axl1p dependent (Adames et al., 1995) and generates ma-
ture a-factor, which is then exported from the cell by the
ABC transporter Ste6p (Berkower and Michaelis, 1991;
Kuchler et al., 1989). It is this extracellular a-factor species
that interacts with MATa cells to initiate the mating pro-
Figure 12. Model for the pathway of a-factor biogenesis. The pre-
cursor species (P0, P1, and P2) and mature (M) species of a-fac-
tor are indicated, and the components of the a-factor biogenesis
machinery are shown. During a-factor biogenesis, unmodified
a-factor precursor (P0) undergoes COOH-terminal modification
(prenylation, proteolytic trimming of AAX, and carboxyl methyla-
tion) to yield the fully modified membrane-associated species (P1).
Next, NH2-terminal proteolytic processing occurs in two distinct
steps, the first removing seven residues from the NH2 terminus to
yield the intermediate precursor (P2), and the second cleavage
generating mature (M) a-factor, which undergoes export from
the cell. The biogenesis components are indicated. The CAAX
processing machinery includes the Ram1p/Ram2p farnesyltrans-
ferase, the genetically unidentified AAX protease, and the
Ste14p methyltransferase. The gene products required for the
NH2-terminal processing of the a-factor precursor are the Ste24p
and Axl1p proteases. The export of a-factor is mediated by the
ABC transporter Ste6p. Whereas Ram1p/Ram2p resides in the cy-
tosol, all the other a-factor biogenesis components appear to be
membrane associated, although the precise cellular membrane(s)
in which they reside are not known. For the sake of simplicity, a
single cellular membrane is shown here. It is unlikely, however,
that the plasma membrane is the site of a-factor processing. For
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cess. Several aspects of the a-factor biogenesis model de-
picted in Fig. 12 are discussed below in the context of the
findings presented in this study.
The NH2-terminal Processing of a-Factor Involves Two 
Sequential Steps
The unexpected a-factor biosynthetic intermediate (P2)
identified in this work reveals that the NH2-terminal cleav-
age of the a-factor precursor is more complex than we
originally envisioned and takes place in two sequential
steps. The first cleavage (P1®P2) occurs between residues
T7 and A8 of the MFA1-encoded a-factor precursor. This
event is followed by a second cleavage (P2®M) between
residues N21 and Y22 to yield mature a-factor.
But is P2 truly an obligatory intermediate in the biogen-
esis of mature a-factor, or is it a dead-end product? In
principle, demonstration of a precursor–product relation-
ship between P2 and M by pulse-chase kinetic studies would
resolve this issue, yet the fact that the P2 does not quanti-
tatively chase to M (Fig. 8) precludes a clear-cut answer to
this question. Other studies in our laboratory do, however,
provide convincing evidence that P2 is indeed an essential
intermediate leading to the formation of mature (M) a-factor.
First, we have isolated a-factor mutants (i.e., mfa1-A8G)
that are blocked in the P1®P2 processing step and are un-
able to generate mature (M) a-factor (Nouvet, F., A. Kis-
tler, and S. Michaelis, manuscript in preparation). Second,
we have isolated a new sterile mutant (ste24) that is defec-
tive in the cellular machinery that carries out P1®P2
processing. This mutant also fails to generate mature (M)
a-factor (Fujimura-Kamada et al., 1997). Together, these
“substrate” and “machinery” mutants provide compelling
evidence that mature a-factor is derived from P2, not P1,
and that the P1®P2 cleavage step (and thus the P2 inter-
mediate) cannot be circumvented.
Recently, the P2®M step of a-factor processing was
shown to be dependent on the AXL1 gene product, which
also plays a role in axial bud site selection in haploid yeast
(Adames et al., 1995; Fujita et al., 1994). Axl1p belongs to
the human insulin-degrading enzyme family of zinc metal-
loproteases, known to cleave small peptide substrates in
vitro and in vivo, most notably insulin (Becker and Roth,
1995). In an axl1 mutant, P2®M processing fails to occur,
whereas Ste24p-dependent P1®P2 processing is unaf-
fected, indicating that the two steps of a-factor NH2-termi-
nal processing involve distinct proteases (Adames et al.,
1995; Fujimura-Kamada et al., 1997). Like Axl1p, Ste24p
is a zinc metalloprotease. It will be of considerable interest
to determine the cellular location of the Axl1p and Ste24p
proteases and to ask whether they directly interact with
one another and have other common substrates, aside
from  a-factor.
We demonstrate here that the P1®P2 cleavage of the
a-factor precursor encoded by MFA1 occurs between resi-
dues T7 and A8, presumably by an endoproteolytic cleav-
age mechanism. Interestingly, we found that a mutation in
the mature portion of MFA1, I23M, which alters a residue
quite distant from the P1®P2 cut site, results in a slightly
altered cleavage site; cleavage occurs between residues T5
and A6, instead of T7 and A8 (Fig. 4). It is possible that
both TA sites are legitimate cleavage sites, with the former
preferred by wild-type MFA1, and the preference reversed
in the mutant context. The MFA2-encoded a-factor pre-
cursor, like that of MFA1, also gives rise to a P2 intermedi-
ate (Fig. 8), although its precise cleavage site has not yet been
determined. Ultimately, a systematic analysis of a-factor
missense mutations located at, near, and distant from the
P1®P2 and P2®M cleavage sites will allow us to define
the minimal rules for recognition and cleavage of a-factor
by its NH2-terminal processing proteases.
Dependence of NH2-terminal Processing upon
COOH-terminal Prenylation
COOH-terminal prenylation is known to play a critical
role for the membrane association of CAAX proteins
(Zhang and Casey, 1996). We provide evidence in this
study and elsewhere that in the biogenesis of the a-factor
precursor, COOH-terminal prenylation is essential for
subsequent NH2-terminal processing (He et al., 1991).
This conclusion is based on the analysis both of a-factor
mutants and of prenyltransferase mutants. In this study,
we generated two a-factor CAAX mutants, mfa1-C33S
and  mfa1-DVIA, in which prenylation of a-factor does not
occur. We show that in these mutants, the nonprenylated
precursor P0 fails to associate with the membrane and fails
to undergo NH2-terminal proteolytic processing (Fig. 6).
Likewise, in mutants defective in the cellular prenylation
machinery (Ram1p-Ram2p), the P0 a-factor precursor is
not NH2-terminally processed (He et al., 1991). Together,
these data provide convincing evidence that COOH-ter-
minal prenylation is a prerequisite for subsequent NH2-
terminal events of a-factor biogenesis. For other CAAX
proteins, prenylation also serves as a key modification that
is required for downstream events. For instance, for Ras
proteins that are modified by both a prenyl and a palmi-
tate moiety, the addition of palmitate requires previous
prenylation (Hancock et al., 1990). Likewise, a proteolytic
processing event required for the functional maturation of
the mammalian and chicken nuclear lamin A protein de-
pends on its previous prenylation (Beck et al., 1990; Hen-
nekes and Nigg, 1994; Sinensky et al., 1994).
Why might NH2-terminal proteolytic processing of the
a-factor precursor depend on COOH-terminal prenyla-
tion? One possibility is that the machinery that carries out
NH2-terminal processing is membrane associated. Accord-
ing to this view, NH2-terminal processing can only occur
when a-factor reaches the membrane, which in turn re-
quires that it be prenylated. Indeed, evidence supporting a
membrane location for most of the a-factor processing ma-
chinery is accumulating (as discussed in the next section).
A second possibility is that the COOH-terminal prenyl
moiety serves as a specific recognition determinant for the
a-factor NH2-terminal protease(s), such that cleavage can-
not occur if the prenyl group is absent from the precursor,
regardless of its localization. Investigation of this possibil-
ity will require in vitro characterization of the substrate
recognition properties of the a-factor NH2-terminal pro-
teases. A role for prenylation in modulating protein–pro-
tein interactions is not unprecedented, and has been dem-
onstrated for Ras and adenylate cyclase in yeast (Horiuchi
et al., 1992), as well as for substrate recognition by the Ste14p
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It should be noted that in contrast to prenylation, car-
boxyl methylation is not required for the NH2-terminal
processing of a-factor, nor for its membrane association,
because in a ste14 mutant, which lacks methyltransferase
activity, the NH2-terminal processing and membrane asso-
ciation of a-factor occur normally (Sapperstein et al., 1994).
Only the export of a-factor is blocked in ste14 mutants,
which has led to the suggestion that the methyl group may
provide a specific recognition determinant for the a-factor
transporter Ste6p (Sapperstein et al., 1994). Likewise,
studies on the membrane localization of Ras indicate that
carboxyl methylation contributes to, but is not absolutely
required for, its membrane association and palmitoylation
(Hancock et al., 1991).
The Biogenesis of a-Factor Is Intimately Associated 
with Membrane(s)
Where do the events of a-factor biogenesis take place?
Our finding that all prenylated a-factor species, P1, P2,
and M, are membrane associated suggests that the cellular
machinery that mediates a-factor maturation is likely to be
localized to a membrane, as depicted in Fig. 12. This view
is further supported by the molecular and biochemical
characterization of a-factor biogenesis components known
to function after the Ram1p/Ram2p prenyltransferase,
which appears to be cytosolic. The COOH-terminal bio-
genesis components (the AAX protease and Ste14p), as
well as the NH2-terminal proteases (Ste24p and Axl1), all
fractionate with membranes (Ashby et al., 1992; Hrycyna and
Clarke, 1990, 1992; Schmidt, W., J. Romano, K. Fujimura-
Kamada, and S. Michaelis, unpublished observations). Fur-
thermore, hydropathy analysis of Ste14p and Ste24p pre-
dict multiple membrane spans, suggesting that these are
both integral membrane proteins (Fujimura-Kamada et al.,
1997; Sapperstein et al., 1994). Together, these results im-
plicate a membrane location as the major site of a-factor
maturation. Analysis of a-factor biogenesis in a ste6 mutant
indicates that the maturation of a-factor is completed be-
fore its membrane translocation; thus, a-factor processing
must be carried out on the cytosolic face of a membrane(s).
What is the precise cellular site where a-factor biogenesis
takes place? While Fig. 12 schematically depicts biogenesis
of a-factor occurring at the plasma membrane, other possi-
bilities can certainly be considered. Either the plasma
membrane or the membranes of intracellular organelles
could provide a site for the processing of the a-factor pre-
cursor. Presumably, the COOH-terminal events shared by
Ras,  a-factor, and other prenylated proteins occur in a
common location, although very little is known about the
intracellular trafficking of any CAAX-terminating pro-
teins. Detailed fractionation analysis is underway to assign
the precise cellular location(s) of the several a-factor inter-
mediates, as well as to determine whether COOH-termi-
nal trimming, methylation, and NH2-terminal proteolytic
processing occur on the same or distinct cellular mem-
branes. Ste6p is localized to the plasma membrane in en-
docytosis mutants (end3, end4, and sac6) that are blocked
for Ste6p internalization to the vacuole (Berkower et al.,
1994; Kolling and Hollenberg, 1994; Paddon et al., 1996).
In these mutants, a-factor export occurs normally, suggesting
that the plasma membrane is the likely site of a-factor export.
Is There a Fundamental Connection between the 
COOH-terminal Modification of a-Factor and its 
Nonclassical Mode of Export?
Two features of a-factor distinguish it from most other ex-
tracellular proteins. One is that a-factor is prenylated and
methylated; these modifications appear to be critical for
receptor binding because a-factor lacking either modifica-
tion is severely reduced in activity (Marcus et al., 1991).
The second is that the export of a-factor is mediated by a
nonclassical exporter, the ABC transporter Ste6p, instead
of by the machinery of the classical secretory pathway
(Michaelis, 1993). Close mammalian relatives of Ste6p,
human MDR1 and mouse MDR3, mediate the transport
across membranes of diverse hydrophobic compounds,
including hydrophobic drugs and prenylcysteine deriva-
tives (Gottesman and Pastan, 1993; Zhang et al., 1994). In-
deed, mouse MDR3 can complement the a-factor export
defect of a ste6 mutant (Raymond et al., 1992). A related
protein, human MDR2, functions as a phosphatidylcholine
flippase (Reutz and Gros, 1994). It is probable that the
a-factor transporter Ste6p and the mammalian MDR pro-
teins share common mechanistic features that make them
particularly suitable for the translocation of highly hydro-
phobic substrates. Notably, at this time, a-factor is the only
secreted protein or peptide known to be prenylated. An
interesting possibility is that a-factor might actually be
precluded from undergoing membrane translocation via
the classical secretory machinery (Rapoport, 1992); for in-
stance, a-factor may be sufficiently hydrophobic because
of its prenyl group, so that it would actually “clog” the ER
translocation pore. Instead, a-factor and certain other hy-
drophobic compounds may thus have an absolute require-
ment for a novel, nonclassical translocation mechanism,
such as that provided by the ABC transporter Ste6p.
The a-Factor Biogenesis Process Exhibits Surprisingly 
Low Efficiency and Distinctive Kinetic Properties
A striking aspect of the a-factor biogenesis pathway re-
vealed by kinetic analysis (Fig. 8) is its low efficiency. Only
a small proportion (,15%) of the a-factor precursor ini-
tially synthesized during a pulse label actually appears in
the culture fluid as mature a-factor. The low biogenesis ef-
ficiency can be explained primarily by the inefficiency of
the P2®M processing step, in that most of the P2 remains
uncleaved and is simply slowly degraded over time. Simi-
larly, the a-factor export step is also somewhat inefficient
in that we observe that a substantial fraction of intracel-
lular mature a-factor is never exported from the cell
(Fig. 8). Why is a-factor biogenesis so inefficient at multi-
ple steps in the processing pathway? One view is that
a-factor biogenesis is processive, requiring an intimate
“hand-off” of the substrate from one component to the
next. Accordingly, any newly formed a-factor intermedi-
ate that is not successfully “handed off” from one biogene-
sis component to the next falls “out of the loop” and can-
not reenter the pathway. We have demonstrated that the
low efficiency of a-factor processing and export is not sim-
ply a peculiarity of our strain background, since it is also
the case in strains from a variety of genetic lineages; in ad-
dition both MFA1- and MFA2-encoded a-factor exhibit
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The P2®M NH2-terminal processing step and, under
certain circumstances (i.e., overexpression), the P1®P2
step, can be considered to be rate limiting for production
of mature a-factor. As such, these would be ideal steps at
which to exert regulation. One obvious time at which opti-
mizing a-factor production might be critical is during mat-
ing. We examined a-factor biogenesis after a-factor treat-
ment. Although we did detect a modest increase in the
overall level of a-factor that was synthesized, processed,
and secreted, the ratio of a-factor intermediates (and thus
the processing efficiency) was not dramatically different
from untreated cells. However, the finding that a-factor
treatment alone does not affect these parameters may not
necessarily reflect a lack of modulation of the a-factor
pathway during actual mating. It will be important to look
at the processing efficiency during the mating process per
se, particularly in light of recent evidence that a high level
of a-factor is necessary for efficient completion of cell fu-
sion during late steps in mating (Brizzio et al., 1996).
Detection of a-Factor Intermediates
The success of this study relied upon the development of
an electrophoresis system suitable to achieve the high res-
olution separation of metabolically labeled a-factor inter-
mediates, which are difficult to separate by conventional
gel electrophoresis because of their very small size (rang-
ing between 12 and 36 amino acids) and their hydropho-
bicity. We expect that the gel system developed here for
the separation of a-factor intermediates will prove to be
useful for examining the biogenesis of other small preny-
lated peptides, including fungal mating pheromones, and
perhaps as yet undiscovered prenylated mammalian hor-
mones.
Implications from a-Factor for the Biogenesis of Other 
Fungal Mating Pheromones
Despite its seeming novelty, the a-factor biogenesis pat-
tern may actually be commonplace in eukaryotic organ-
isms. In recent years, more than half a dozen fungal
mating pheromones have been shown either by DNA se-
quence analysis or by mass spectrometry to share certain
features in common with a-factor, notably a COOH-termi-
nal CAAX motif or a prenylated cysteine (with or without
a carboxyl methyl group; reviewed in Caldwell et al.,
1995). Examples of such pheromones include: Schizosac-
charomyces pombe M-factor (Davey, 1992), Ustilago may-
dis a1 and a2 factors (Bolker et al., 1992; Spellig et al.,
1994), Cryptococcus neoformans a-factor (Moore and Ed-
man, 1993), Tremella mesenterica tremerogens A-10 and
a-13 (Sakagami et al., 1981), Tremella brasilliensis trem-
erogens A-9291-I, 2, and 3 (Ishibashi et al., 1984), and
Rhodotorucine toruloides rhodotorucine A (Akada et al.,
1989; Kamiya et al., 1979). We have recently discovered
another fungal pheromone, L-factor, produced by the
yeast  Saccharomycodes ludwigii. Interestingly, L-factor is
capable of inducing mating type-specific responses in MATa
cells of S. cerevisiae despite the fact S. ludwigii and S. cere-
visiae do not appear to be closely related organisms (Kist-
ler, A., and S. Michaelis, manuscript in preparation).
It is of historical note that the first evidence that iso-
prenoids could modify polypeptides came from studies of
the fungal pheromones tremerogen and rhodotorucine
(Kamiya et al., 1979; Sakagami et al., 1981). Although ori-
ginally thought to represent a fungal specialization, these
findings heralded studies that ultimately led to the discov-
ery that numerous eukaryotic proteins are prenylated and
that prenylation imparts functionally significant properties
to these proteins (Zhang and Casey, 1996). In recent years,
DNA sequence analysis has highlighted yet another fea-
ture that is common to at least several fungal pheromones
(i.e., S. pombe M-factor, U. maydis a1 and a2 factors, and
C. neoformans a-factor) in addition to their CAAX motif.
Like the S. cerevisiae a-factor precursor, these phero-
mones are predicted to contain an NH2-terminal extension
that lacks the features of a canonical signal sequence.
Thus, it is tempting to propose, by analogy to S. cerevisiae
a-factor, that these pheromones will all prove to be COOH-
terminally modified, NH2-terminally processed, and se-
creted by a nonclassical mechanism. Were this the case,
then these pheromones might make use of a similar array
of biogenesis components as does S. cerevisiae a-factor. To
date, evidence supporting this notion is most compelling
for S. pombe M-factor. Mass spectrometry has shown that
M-factor is a prenylated and carboxyl methylated non-
amer, and the M-factor gene sequences provide evidence
for an NH2-terminal extension (30 and 32 amino acids long
for mfm1 and mfm2, respectively) in addition to a COOH-
terminal CAAX motif (Davey, 1992). Perhaps not surpris-
ingly, two S. pombe genes required for M-factor produc-
tion, mam4 and mam1, have been shown to encode homo-
logues of S. cerevisiae a-factor biogenesis components STE14
and  STE6, respectively (Davey, J., and M. Yamamoto,
personal communication).
It is not understood why S. cerevisiae a-factor and a-fac-
tor use distinct pathways for biogenesis despite their func-
tional equivalence. Interestingly, while S. pombe cells of
opposite mating type (M and P), like S. cerevisiae MATa
and MATa cells, produce a prenylated and a nonpreny-
lated pheromone, respectively, this situation is not universal
among fungi. In U. maydis, for instance, cells of the oppo-
site mating type both encode mating factors that terminate
with a CAAX motif (Spellig et al., 1994). Interestingly, in
the case of the pathogenic fungus C. neoformans, pathoge-
nicity is cell type specific, with the a cell type exhibiting
the higher degree of virulence (Moore and Edman, 1993).
If it is indeed the case that the C. neoformans a-factor
pheromone is itself directly responsible for the organism’s
pathogenicity, then understanding the mechanism of pher-
omone biogenesis might provide a rational basis for thera-
peutic intervention.
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